MedTrace Logo

The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

NCT01102140 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-14

Study results available
· View outcomes & findings →

Summary

This blinded, controlled study will examine the impact of pomegranate polyphenol extract (POMx, from Pom Wonderful, LLC), 1000mg on cardiomyopathy in subjects with chronic renal insufficiency.

Conditions

Interventions

DRUG

POMx, pomegranate polyphenol extract

1000 mg orally once daily.

DRUG

Sugar Pill

Matching sugar pill

Sponsors & Collaborators

  • POM Wonderful LLC

    collaborator INDUSTRY

  • Jennifer Cowger , MD, MS

    lead OTHER

Principal Investigators

  • Jennifer C Matthews, MD, MS · Univeristy of Michigan Health System

  • Bertram Pitt, MD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102140 on ClinicalTrials.gov